Aristotle Capital Boston, LLC Supernus Pharmaceuticals, Inc. Transaction History

Aristotle Capital Boston, LLC

$1.87 Billion
Q3 2025

A detailed history of Aristotle Capital Boston, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Aristotle Capital Boston, LLC holds 305,273 shares of SUPN stock, worth $13.7 Million. This represents 0.78% of its overall portfolio holdings.

Number of Shares

305,273

Previous 808,395 62.24%

Holding current value

$13.7 Million

Previous $25.5 Million 42.75%

% of portfolio

0.78%

Previous 1.34%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$31.45 - $47.79 $15.8 Million - $24 Million	-503,122 Reduced 62.24%	305,273 $14.6 Million
Q2 2025 Aug 14, 2025	SELL	$30.29 - $33.43 $1.95 Million - $2.15 Million	-64,293 Reduced 7.37%	808,395 $25.5 Million
Q1 2025 May 15, 2025	SELL	$31.17 - $40.0 $6.33 Million - $8.13 Million	-203,180 Reduced 18.89%	872,688 $28.6 Million
Q4 2024 Feb 14, 2025	SELL	$31.89 - $37.83 $3.77 Million - $4.48 Million	-118,358 Reduced 9.91%	1,075,868 $38.9 Million
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $230,383 - $314,330	-8,940 Reduced 0.74%	1,194,226 $37.2 Million

Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $1.65 Million - $2.14 Million	63,320 Added 5.56%	1,203,166 $32.2 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $541,712 - $702,766	-19,982 Reduced 1.72%	1,139,846 $38.9 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $639,636 - $835,581	-28,153 Reduced 2.37%	1,159,828 $33.6 Million
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $717,757 - $856,778	26,034 Added 2.24%	1,187,981 $32.8 Million
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $203,328 - $263,286	6,798 Added 0.59%	1,161,947 $34.9 Million
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $987,401 - $1.19 Million	28,268 Added 2.51%	1,155,149 $41.9 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $953,592 - $1.16 Million	-30,672 Reduced 2.65%	1,126,881 $40.2 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $3.17 Million - $3.9 Million	-110,187 Reduced 8.69%	1,157,553 $39.2 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $245,017 - $331,300	9,673 Added 0.77%	1,267,740 $36.7 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $792,720 - $914,784	-27,805 Reduced 2.16%	1,258,067 $40.7 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $850,089 - $1.1 Million	-32,237 Reduced 2.45%	1,285,872 $37.5 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $6.04 Million - $8.05 Million	256,456 Added 24.16%	1,318,109 $35.2 Million
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $2.36 Million - $2.93 Million	88,360 Added 9.08%	1,061,653 $32.7 Million
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $1.17 Million - $1.52 Million	-48,333 Reduced 4.73%	973,293 $25.5 Million
Q4 2020 Feb 22, 2021	BUY	$17.7 - $25.81 $134,874 - $196,672	7,620 Added 0.75%	1,021,626 $25.7 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $1.03 Million - $1.51 Million	-58,446 Reduced 5.45%	1,014,006 $25.5 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $901,202 - $1.12 Million	44,614 Added 4.34%	1,072,452 $22.4 Million
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $4.91 Million - $7.15 Million	287,199 Added 38.78%	1,027,838 $24.4 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $243,684 - $416,372	-16,864 Reduced 2.23%	740,639 $13.3 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $269,274 - $393,575	13,511 Added 1.82%	757,503 $18 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $16.3 Million - $21.4 Million	639,961 Added 615.16%	743,992 $20.4 Million
Q2 2019 Mar 04, 2020	BUY	$29.96 - $38.87 $1.05 Million - $1.36 Million	35,089 Added 50.9%	104,031 $3.44 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $2.07 Million - $2.68 Million	68,942 New	68,942 $2.28 Million

Others Institutions Holding SUPN

# of Institutions

331

Shares Held

60.2M

Call Options Held

234K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.41B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aristotle Capital Boston, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aristotle Capital Boston, LLC with notifications on news.

Account

Aristotle Capital Boston, LLC Supernus Pharmaceuticals, Inc. Transaction History